Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

06.02.23	Sage Therapeutics: FDA To Review NDA For Zuranolone - Quick Facts (RTTNews)
30.01.23	Eisai : Lecanemab Receives Priority Review Status In Japan For Alzheimer's Disease Treatment (RTTNews)
30.01.23	LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN (PR Newswire)
27.01.23	Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease (RTTNews)
27.01.23	MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY (PR Newswire)
16.01.23	EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN (PR Newswire)
11.01.23	Eisai Submits MAA For Lecanemab As Treatment For Early Alzheimer's Disease In Europe (RTTNews)
11.01.23	EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE (PR Newswire)
07.01.23	Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease Treatment (RTTNews)
07.01.23	FDA Approves Eisai And Biogen's Leqembi For Alzheimer's Disease Treatment (RTTNews)
07.01.23	Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease (PR Newswire)
06.01.23	FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease (PR Newswire)
04.01.23	Biogen Announces License Agreement With Alcyone For ThecaFlex DRx System (RTTNews)
30.12.22	Congress Report Says FDA Broke Protocols In Approval Of Biogen Alzheimer's Drug (RTTNews)
23.12.22	EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA (PR Newswire)
19.12.22	Biogen Signs Agreement With Genentech For Royalties On Glofitamab (RTTNews)
09.12.22	Biogen : FDA Accepts BLA For BIIB800, Biosimilar Candidate Referencing ACTEMRA (RTTNews)
05.12.22	Biogen's Tofersen MAA Accepted In Europe To Treat Rare, Genetic Form Of ALS (RTTNews)
30.11.22	Eisai Clarifies Lecanemab Not Associated With Two Deaths In Alzheimer's Disease Treatment Trial (RTTNews)
30.11.22	ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGL... (PR Newswire)
30.11.22	EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE (PR Newswire)
29.11.22	Eisai, Biogen Hit By 2nd Death Related To Alzheimer Trial Drug (RTTNews)
21.11.22	Form 3 875045 (RSS)
10.11.22	Biogen Appoints Christopher Viehbacher As President And CEO (RTTNews)
10.11.22	Biogen Names Christopher Viehbacher President and Chief Executive Officer (GlobeNewswire)
10.11.22	Form 8-K 875045 (RSS)
28.10.22	Form 4 875045 (RSS)
26.10.22	Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS (GlobeNewswire)
26.10.22	New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS (GlobeNewswire)
25.10.22	Biogen Raises 2022 Guidance (RTTNews)
25.10.22	Form 8-K 875045 (RSS)
25.10.22	Form 10-Q 875045 (RSS)
17.10.22	Sage Therapeutics, Biogen Report Further Analyses From Zuranolone Trial In Postpartum Depression (RTTNews)
17.10.22	Biogen: FDA Extends Review Period Of NDA For Tofersen - Quick Facts (RTTNews)
17.10.22	Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen (GlobeNewswire)
13.10.22	SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm (PR Newswire)
30.09.22	Biogen: EMA To Review MAA For BIIB800 - Quick Facts (RTTNews)
30.09.22	Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab) (GlobeNewswire)
28.09.22	Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… (RTTNews)
28.09.22	Biogen And Eisai's Lecanemab Slows Progression Of Alzheimer's Disease In Phase 3 Trial (RTTNews)
28.09.22	LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WI... (PR Newswire)
27.09.22	Biogen Agrees To Pay $900 Mln Over Kickback Allegations (RTTNews)
21.09.22	The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS (GlobeNewswire)
13.09.22	SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm (PR Newswire)
07.09.22	The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus (GlobeNewswire)
04.08.22	EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFE... (PR Newswire)
28.07.22	The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus (GlobeNewswire)
26.07.22	FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS (GlobeNewswire)
21.07.22	ABT Raises Earnings Forecast, BIIB Provides Rosy Revenue Outlook, ELV Q2 Revenue Up 15.6% (RTTNews)
20.07.22	Biogen Boosts FY22 Outlook As Q2 Results Top Estimates (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16.05.25		Aktien von BMW, BASF, Bayer und Co.: DAX-Konzerne vermelden deutlich weniger Gewinn
16.05.25		DAX 40-Wert Bayer-Aktie: So viel hätten Anleger an einem Bayer-Investment von vor 3 Jahren verloren
15.05.25		Bayer-Analyse: Goldman Sachs Group Inc. stuft Bayer-Aktie mit Neutral ein
13.05.25		Bayer-Aktie zieht an: Bayer startet besser als erwartet ins Jahr - Pharma-Sparte glänzt
13.05.25		QIAGEN-Aktie gewinnt: QIAGEN stärkt digitales Genomik-Portfolio mit Genoox-Übernahme
13.05.25		Bayer-Aktie: Jüngste Einstufung durch DZ BANK
13.05.25		Aktienempfehlung Bayer-Aktie: JP Morgan Chase & Co. bewertet Anteilsschein in neuer Analyse
13.05.25		Neue Analyse: Deutsche Bank AG bewertet Bayer-Aktie mit Hold

16.05.25

Aktien von BMW, BASF, Bayer und Co.: DAX-Konzerne vermelden deutlich weniger Gewinn

16.05.25

DAX 40-Wert Bayer-Aktie: So viel hätten Anleger an einem Bayer-Investment von vor 3 Jahren verloren

15.05.25

Bayer-Analyse: Goldman Sachs Group Inc. stuft Bayer-Aktie mit Neutral ein

13.05.25

Bayer-Aktie zieht an: Bayer startet besser als erwartet ins Jahr - Pharma-Sparte glänzt

13.05.25

QIAGEN-Aktie gewinnt: QIAGEN stärkt digitales Genomik-Portfolio mit Genoox-Übernahme

13.05.25

Bayer-Aktie: Jüngste Einstufung durch DZ BANK

13.05.25

Aktienempfehlung Bayer-Aktie: JP Morgan Chase & Co. bewertet Anteilsschein in neuer Analyse

13.05.25

Neue Analyse: Deutsche Bank AG bewertet Bayer-Aktie mit Hold

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	165.65	6.94 %	K V
Sonova Hldg	282.70	2.84 %	K V
Alcon	74.88	2.41 %	K V
Kuehne+Nagel Int	194.50	1.30 %	K V
Lonza Grp	573.60	1.27 %	K V
Nestle	86.48	-0.13 %	K V
Part Grp Hldg	1’182.50	-0.63 %	K V
Swiss Re	148.40	-0.84 %	K V
Logitech Intl	72.12	-1.74 %	K V
Swiss Life Hldg	808.20	-2.98 %	K V

Biogen Aktie VALOR 1720684 / ISIN US09062X1037

Nachrichten zu Biogen Inc

Aktien Top/Flop

Biogen Peer Group Nachrichten

Meistgelesene Nachrichten